Deciphering the role of RET in cancer and breakthroughs in targeted treatments

FHS
July 19, 2024
4:49 am

Xueqing Hu , Ujjwol Khatri , Tao Shen , and Jie Wu, at University of Oklahoma Health Sciences Center, USA, provides a comprehensive review of the role of the RET (REarranged during Transfection) receptor tyrosine kinase in cancer development and the advancements in RET-targeted cancer therapies.

CD22-targeted CAR-T therapy shows promising results in relapsed large B-cell lymphoma

CAR-T cell therapy, which targets a specific protein on the surface of cancer cells, causes tumors to shrink or disappear in about half of patients

July 11, 2024

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder | Psychedelic Invest

TORONTO–(BUSINESS WIRE)–Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental healthcare by developing new and innovative

August 13, 2024

Study Pinpoints Growing Use of Cannabis to Manage Menopause Symptoms

PHILADELPHIA — One in 10 midlife women said they used cannabis in the past month, some of which was to manage menopausal symptoms, a researcher

October 2, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.